hydroxychloroquine has been researched along with Scleroderma, Systemic in 21 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A fasciitis-sclerodermia-eosinophilia syndrome developed in four female patients, aged between 55 and 75 years, after the ingestion of tryptophan, 1." | 7.68 | [Tryptophan-induced fasciitis-scleroderma-eosinophilia syndrome]. ( Gross, WL; Reinhold-Keller, E; Schnabel, A; Wolff, HH, 1991) |
| "There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak." | 5.62 | Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. ( Abreu, MM; Albuquerque, CP; Araújo, NC; Bacchiega, AB; Bianchi, DV; Bica, B; Bonfa, ED; Borba, EF; Brito, DCSE; de Souza, VA; Duarte, ÂLBP; Fernandes, PR; Ferreira, GA; Gomes, KWP; Guimarães, MP; Junior, LFR; Kakehasi, AM; Klumb, EM; Lacerda, MVG; Lanna, CCD; Marques, CDL; Monticielo, OA; Mota, LMH; Munhoz, GA; Paiva, ES; Pereira, HLA; Pileggi, GS; Pinheiro, MM; Provenza, JR; Reis, APMG; Reis-Neto, ET; Ribeiro, SLE; Sampaio, CSJC; Sampaio, VS; Santo, RCE; Sato, EI; Skare, T; Valim, V; Xavier, RM, 2021) |
| " For inflammatory arthritis, 79% of experts agreed (first- through fourth-line treatments were MTX, low-dose glucocorticoids, hydroxychloroquine, and rituximab or tocilizumab, respectively)." | 3.88 | Treatment Algorithms for Systemic Sclerosis According to Experts. ( Fernández-Codina, A; Pope, JE; Walker, KM, 2018) |
| "A fasciitis-sclerodermia-eosinophilia syndrome developed in four female patients, aged between 55 and 75 years, after the ingestion of tryptophan, 1." | 3.68 | [Tryptophan-induced fasciitis-scleroderma-eosinophilia syndrome]. ( Gross, WL; Reinhold-Keller, E; Schnabel, A; Wolff, HH, 1991) |
| "Disabling pansclerotic morphea of childhood (DPMC) is a rare subtype of juvenile localized scleroderma (JLS) characterized by pansclerosis mainly affecting children under the age of 14." | 2.61 | Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review. ( Cox, A; Heaton, V; Munro, J; Renton, WD; Samuel, C; Soh, HJ, 2019) |
| "In the 1980's, pregnancies in systemic sclerosis (SSc) patients were considered to be at high risk for poor foetal and maternal outcome." | 2.44 | [Pregnancy in systemic sclerosis]. ( Bérezné, A; Mouthon, L, 2008) |
| "Nodular scleroderma or keloidal morphea presenting in a linear distribution is even more uncommon." | 1.72 | Questions raised by a case of adult-onset linear nodular scleroderma. ( Hansen, CB; Jimenez, A; Marcelus, C; Sontheimer, RD; Zussman, J, 2022) |
| "There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak." | 1.62 | Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. ( Abreu, MM; Albuquerque, CP; Araújo, NC; Bacchiega, AB; Bianchi, DV; Bica, B; Bonfa, ED; Borba, EF; Brito, DCSE; de Souza, VA; Duarte, ÂLBP; Fernandes, PR; Ferreira, GA; Gomes, KWP; Guimarães, MP; Junior, LFR; Kakehasi, AM; Klumb, EM; Lacerda, MVG; Lanna, CCD; Marques, CDL; Monticielo, OA; Mota, LMH; Munhoz, GA; Paiva, ES; Pereira, HLA; Pileggi, GS; Pinheiro, MM; Provenza, JR; Reis, APMG; Reis-Neto, ET; Ribeiro, SLE; Sampaio, CSJC; Sampaio, VS; Santo, RCE; Sato, EI; Skare, T; Valim, V; Xavier, RM, 2021) |
| "Hydroxychloroquine (HCQ) is an antimalarial drug with immunomodulatory effects used to treat systemic lupus erythematosus (SLE) and scleroderma." | 1.56 | Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. ( Alhamad, T; Axelrod, D; Brennan, DC; Caliskan, Y; Chang, SH; Hess, GP; Kasiske, BL; Lam, NN; Lentine, KL; McAdams-DeMarco, M; Schnitzler, MA; Segev, DL; Xiao, H, 2020) |
| "The first case, in a patient with systemic lupus erythematosus, was found to have megamitochondria in addition to myelin figures seen by electron microscopy." | 1.34 | New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases. ( Barouch, LA; Champion, HC; Halushka, MK; Soong, TR; Wigley, FM, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (19.05) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 6 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Pileggi, GS | 1 |
| Ferreira, GA | 1 |
| Reis, APMG | 1 |
| Reis-Neto, ET | 1 |
| Abreu, MM | 1 |
| Albuquerque, CP | 1 |
| Araújo, NC | 1 |
| Bacchiega, AB | 1 |
| Bianchi, DV | 1 |
| Bica, B | 1 |
| Bonfa, ED | 1 |
| Borba, EF | 1 |
| Brito, DCSE | 1 |
| Duarte, ÂLBP | 1 |
| Santo, RCE | 1 |
| Fernandes, PR | 1 |
| Guimarães, MP | 1 |
| Gomes, KWP | 1 |
| Kakehasi, AM | 1 |
| Klumb, EM | 1 |
| Lanna, CCD | 1 |
| Marques, CDL | 1 |
| Monticielo, OA | 1 |
| Mota, LMH | 1 |
| Munhoz, GA | 1 |
| Paiva, ES | 1 |
| Pereira, HLA | 1 |
| Provenza, JR | 1 |
| Ribeiro, SLE | 1 |
| Junior, LFR | 1 |
| Sampaio, CSJC | 1 |
| Sampaio, VS | 1 |
| Sato, EI | 1 |
| Skare, T | 1 |
| de Souza, VA | 1 |
| Valim, V | 1 |
| Lacerda, MVG | 1 |
| Xavier, RM | 1 |
| Pinheiro, MM | 1 |
| Ponfilly-Sotier, MP | 3 |
| Mahevas, T | 3 |
| Rivière, S | 3 |
| Dellal, A | 3 |
| Belfeki, N | 3 |
| Carrat, F | 3 |
| Fain, O | 3 |
| Mekinian, A | 3 |
| Marcelus, C | 1 |
| Jimenez, A | 1 |
| Zussman, J | 1 |
| Hansen, CB | 1 |
| Sontheimer, RD | 1 |
| Otman, E | 1 |
| Gucenmez, S | 1 |
| Solmaz, D | 1 |
| Akar, S | 1 |
| Ozmen, M | 1 |
| Bellan, M | 1 |
| Parisi, S | 1 |
| Stobbione, P | 1 |
| Pedrinelli, AR | 1 |
| Rizzi, E | 1 |
| Casciaro, GF | 1 |
| Vassia, V | 1 |
| Landi, R | 1 |
| Cittone, MG | 1 |
| Rigamonti, C | 1 |
| Patrucco, F | 1 |
| Ditto, MC | 1 |
| Finucci, A | 1 |
| Realmuto, C | 1 |
| Todoerti, M | 1 |
| Parodi, M | 1 |
| Rossi, P | 1 |
| Pirisi, M | 1 |
| Fusaro, E | 1 |
| Sainaghi, PP | 1 |
| Lentine, KL | 1 |
| Lam, NN | 1 |
| Caliskan, Y | 1 |
| Alhamad, T | 1 |
| Xiao, H | 1 |
| Schnitzler, MA | 1 |
| Chang, SH | 1 |
| Axelrod, D | 1 |
| Segev, DL | 1 |
| McAdams-DeMarco, M | 1 |
| Kasiske, BL | 1 |
| Hess, GP | 1 |
| Brennan, DC | 1 |
| Allard, A | 1 |
| Healy, R | 1 |
| Bristow, E | 1 |
| Hickey, S | 1 |
| Fernández-Codina, A | 1 |
| Walker, KM | 1 |
| Pope, JE | 1 |
| Soh, HJ | 1 |
| Samuel, C | 1 |
| Heaton, V | 1 |
| Renton, WD | 1 |
| Cox, A | 1 |
| Munro, J | 1 |
| Basta, F | 1 |
| Irace, R | 1 |
| Borgia, A | 1 |
| Messiniti, V | 1 |
| Riccardi, A | 1 |
| Valentini, G | 1 |
| Afeltra, A | 1 |
| Khayat, R | 1 |
| Dupuy, A | 1 |
| Pansé, I | 1 |
| Bagot, M | 1 |
| Cordoliani, F | 1 |
| Bruni, C | 1 |
| Praino, E | 1 |
| Guiducci, S | 1 |
| Bellando-Randone, S | 1 |
| Furst, DE | 1 |
| Matucci-Cerinic, M | 1 |
| Abdin, A | 1 |
| Pöss, J | 1 |
| Kandolf, R | 1 |
| Thiele, H | 1 |
| Bérezné, A | 1 |
| Mouthon, L | 1 |
| RUGGIERO, HA | 1 |
| Soong, TR | 1 |
| Barouch, LA | 1 |
| Champion, HC | 1 |
| Wigley, FM | 1 |
| Halushka, MK | 1 |
| Shearer, RV | 1 |
| Dubois, EL | 1 |
| Schaller, JG | 1 |
| Schnitzler, L | 1 |
| Verret, JL | 1 |
| Schnabel, A | 1 |
| Reinhold-Keller, E | 1 |
| Wolff, HH | 1 |
| Gross, WL | 1 |
| Henkind, P | 1 |
| Gold, DH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effectiveness of ECP in Diffuse Cutaneous Systemic Sclerosis[NCT04986605] | Phase 2 | 15 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| Pragmatic Clinical Trials in Scleroderma[NCT03610217] | 400 participants (Anticipated) | Interventional | 2018-10-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxychloroquine and Scleroderma, Systemic
| Article | Year |
|---|---|
Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.
Topics: Antirheumatic Agents; Biological Products; Biopsy; Child, Preschool; Contracture; Edema; Hematopoiet | 2019 |
[Pregnancy in systemic sclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Female; Fetal Diseases; Humans; Hydr | 2008 |
Ocular manifestations of rheumatic disorders. Natural and iatrogenic.
Topics: Adrenal Cortex Hormones; Arteritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Chloroquine; Conjunc | 1973 |
18 other studies available for hydroxychloroquine and Scleroderma, Systemic
| Article | Year |
|---|---|
Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Chi-Square Dist | 2021 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Absence of evidence for the efficacy of hydroxychloroquine in systemic sclerosis: Data from case-control monocentric study.
Topics: Antirheumatic Agents; Case-Control Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2023 |
Questions raised by a case of adult-onset linear nodular scleroderma.
Topics: Adult; Female; Humans; Hydroxychloroquine; Keloid; Scleroderma, Localized; Scleroderma, Systemic; Sk | 2022 |
Hydroxychloroquine might reduce mortality in patients with systemic sclerosis.
Topics: Humans; Hydroxychloroquine; Patients; Scleroderma, Localized; Scleroderma, Systemic | 2023 |
Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Cohort Studies; COVID-19; Female; Humans; Hydroxychlo | 2020 |
Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Graft Rejection; Graf | 2020 |
Hydroxychloroquine-induced retinal toxicity in an asymptomatic patient.
Topics: Aged; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Scleroderm | 2018 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
Hydroxychloroquine significantly reduces serum markers of endothelial injury and NEMO videocapillaroscopy score in systemic sclerosis.
Topics: Adult; Aged; Antirheumatic Agents; Biomarkers; Endothelium, Vascular; Female; Humans; Hydroxychloroq | 2019 |
[Sclerodermatous changes in porphyria cutanea tarda: six cases].
Topics: Adrenal Cortex Hormones; Aged; Alcoholism; Alopecia; Diagnosis, Differential; Female; Humans; Hydrox | 2013 |
Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center.
Topics: Arthritis; Cohort Studies; Comorbidity; Databases, Factual; Female; Follow-Up Studies; Humans; Hydro | 2017 |
Hydroxychloroquine-induced cardiomyopathy in a patient with limited cutaneous systemic sclerosis.
Topics: Antirheumatic Agents; Cardiomyopathies; Echocardiography; Female; Humans; Hydroxychloroquine; Magnet | 2017 |
[TREATMENT OF COLLAGEN DISEASES].
Topics: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Collagen Diseases; Dermatomyosit | 1963 |
New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases.
Topics: Aged; Antirheumatic Agents; Cardiomyopathies; Female; Humans; Hydroxychloroquine; Lupus Erythematosu | 2007 |
Ocular changes induced by long-term hydroxychloroquine (plaquenil) therapy.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Child; Cornea; Eye Diseases; Female; Fluoresceins; H | 1967 |
Therapy for childhood rheumatic diseases. Have we been doing enough?
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Child; Child, Pr | 1993 |
[Polymorphic lysosomal inclusions during treatment of generalized scleroderma with synthetic antimalarial drugs. (Cutaneous ultrastructural study)].
Topics: Aged; Female; Humans; Hydroxychloroquine; Lysosomes; Scleroderma, Systemic; Skin | 1979 |
[Tryptophan-induced fasciitis-scleroderma-eosinophilia syndrome].
Topics: Aged; Creatine Kinase; Diagnosis, Differential; Eosinophilia; Fasciitis; Female; Fructose-Bisphospha | 1991 |